Mesalamine for Colorectal Cancer Prevention Programme in Lynch syndrome (MesaCAPP): a multicentre, multinational, randomised, two-arm, double-blind, phase II clinical study with mesalamine or placebo in carriers with Lynch syndrome - a study protocol.

Backman AS, Frank A, Lindberg LJ, Ljungman D, Silander G, Gustafsson RJ, Bozsó T, Schmidt PT, Ingre M, Mittlbock M, Löwbeer C, Marsal J, Lindblom A, Tham E, Therkildsen C, Gasche C, International MesaCAPP Study Group

Open source

DOI: 10.1136/bmjopen-2025-100082
Published: 2025 Nov 9
Container: BMJ open
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/bmjopen-2025-100082,
  title = {Mesalamine for Colorectal Cancer Prevention Programme in Lynch syndrome (MesaCAPP): a multicentre, multinational, randomised, two-arm, double-blind, phase II clinical study with mesalamine or placebo in carriers with Lynch syndrome - a study protocol.},
  author = {Backman AS and Frank A and Lindberg LJ and Ljungman D and Silander G and Gustafsson RJ and Bozsó T and Schmidt PT and Ingre M and Mittlbock M and Löwbeer C and Marsal J and Lindblom A and Tham E and Therkildsen C and Gasche C and International MesaCAPP Study Group},
  year = {2025},
  journal = {BMJ open},
  doi = {10.1136/bmjopen-2025-100082},
  url = {https://doi.org/10.1136/bmjopen-2025-100082}
}

RIS

TY  - JOUR
TI  - Mesalamine for Colorectal Cancer Prevention Programme in Lynch syndrome (MesaCAPP): a multicentre, multinational, randomised, two-arm, double-blind, phase II clinical study with mesalamine or placebo in carriers with Lynch syndrome - a study protocol.
AU  - Backman AS
AU  - Frank A
AU  - Lindberg LJ
AU  - Ljungman D
AU  - Silander G
AU  - Gustafsson RJ
AU  - Bozsó T
AU  - Schmidt PT
AU  - Ingre M
AU  - Mittlbock M
AU  - Löwbeer C
AU  - Marsal J
AU  - Lindblom A
AU  - Tham E
AU  - Therkildsen C
AU  - Gasche C
AU  - International MesaCAPP Study Group
PY  - 2025
JO  - BMJ open
DO  - 10.1136/bmjopen-2025-100082
UR  - https://doi.org/10.1136/bmjopen-2025-100082
ER  -

APA

AS, B., A, F., LJ, L., D, L., G, S., RJ, G., T, B., PT, S., M, I., M, M., C, L., J, M., A, L., E, T., C, T., C, G., & Group, I. M. S. (2025). Mesalamine for Colorectal Cancer Prevention Programme in Lynch syndrome (MesaCAPP): a multicentre, multinational, randomised, two-arm, double-blind, phase II clinical study with mesalamine or placebo in carriers with Lynch syndrome - a study protocol.. BMJ open. https://doi.org/10.1136/bmjopen-2025-100082

Source records

pubmed · retrieved 2026-09-27T06:44:30.313Z